GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Drug: Matching Placebo
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2019-08-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 68
- Registration Number
- NCT03154086
- Locations
- π¦πΊ
GSK Investigational Site, Adelaide, South Australia, Australia
Study of Subjects With Diabetic Foot Ulcer (DFU)
- Conditions
- Diabetic Foot
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT03153007
- Locations
- πΊπΈ
GSK Investigational Site, Bethesda, Maryland, United States
The Extended Salford Lung Study ("Ex-SLS") Data Access Project
- Conditions
- Asthma
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 3500
- Registration Number
- NCT03152669
- Locations
- π¬π§
GSK Investigational Site, Manchester, United Kingdom
Occurrence of Potential Bacterial and Viral Pathogens in Stable Chronic Obstructive Pulmonary Disease and During Acute Exacerbations of the Disease, in Asia Pacific
- Conditions
- Respiratory Disorders
- Interventions
- Other: Sputum and blood sampling
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 197
- Registration Number
- NCT03151395
- Locations
- π¨π³
GSK Investigational Site, Taipei, Taiwan
Bioequivalence Study Between GR37547 500 Milligrams (mg) Tablet Versus Ciprofloxacin 500 mg Tablet Reference Product in Healthy Adult Subjects
- Conditions
- Infections, Bacterial
- Interventions
- Drug: GR37547 tablet
- First Posted Date
- 2017-05-11
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26
- Registration Number
- NCT03150082
- Locations
- πΏπ¦
GSK Investigational Site, Bloemfontein,, South Africa
Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer
- Conditions
- Solid Tumours
- Interventions
- First Posted Date
- 2017-05-11
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 73
- Registration Number
- NCT03150056
- Locations
- π¬π§
GSK Investigational Site, Glasgow, United Kingdom
Cryobiopsy Study to Assess Drug Distribution in Subjects With Suspected Interstitial Lung Disease
- Conditions
- Lung Diseases, Interstitial
- Interventions
- Procedure: Flexible Bronchoscopy/Biopsy
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2019-01-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 8
- Registration Number
- NCT03136120
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
Study of Danirixin in Japanese Healthy Elderly Male Subjects
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2019-04-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 34
- Registration Number
- NCT03136380
- Locations
- π―π΅
GSK Investigational Site, Tokyo, Japan
Determination of the Sun Protection Factor (SPF) of a Cosmetic Daily De-fence Skin Cream
- Conditions
- Sunscreening Agents
- Interventions
- Other: Physiogel Daily Defence Protective Day Cream Light
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2019-04-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26
- Registration Number
- NCT03136107
- Locations
- π©πͺ
GSK Investigational Site, Schenefeld, Schleswig-Holstein, Germany
Prevalence of Severe Asthma in Spanish Hospitals
- Conditions
- Asthma
- Interventions
- Other: QuestionnaireOther: Software of Big Data
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2020-09-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 356
- Registration Number
- NCT03137043
- Locations
- πͺπΈ
GSK Investigational Site, Zaragoza, Spain